Notable companies
The most notable companies in this group are Abbott Laboratories (null:ABT), Intuitive Surgical (null:ISRG), Medtronic plc (null:MDT), Boston Scientific Corp (null:BSX), Edwards Lifesciences Corp (null:EW), IQVIA Holdings (null:IQV), Align Technology (null:ALGN), Illumina (null:ILMN), Exact Sciences Corp (null:EXAS), Guardant Health (null:GH).
Industry description
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Market Cap
The average market capitalization across the Medical Specialties Industry is 7.89B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.
High and low price notable news
The average weekly price growth across all stocks in the Medical Specialties Industry was -2%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -3%. MDXHF experienced the highest price growth at 76%, while CNTGF experienced the biggest fall at -64%.
Volume
The average weekly volume growth across all stocks in the Medical Specialties Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -9%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 74
Price Growth Rating: 60
SMR Rating: 85
Profit Risk Rating: 87
Seasonality Score: 13 (-100 ... +100)